Single Center Experience with Use of Letermovir for CMV Prophylaxis or Treatment in Thoracic Organ Transplant Recipients.

Shambhu Aryal,Shalika B Katugaha,Adam Cochrane,A Whitney Brown,Steven D Nathan,Oksana A Shlobin,Kareem Ahmad,Lauren Marinak,Jessica Chun,Margaret Fregoso,Shashank Desai,Christopher King

Transplant infectious disease : an official journal of the Transplantation Society（2019）

引用 34|浏览13

暂无评分

摘要

Letermovir was well tolerated with only minor side effects reported; however, the rate of development of CMV DNAemia on prophylaxis was considerable. Further study of the dosing and efficacy of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients is warranted. This article is protected by copyright. All rights reserved.

查看译文

关键词

cytomegalovirus, heart transplantation, letermovir, lung transplantation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要